“We are pleased with our results from the fourth quarter, where we grew revenue meaningfully quarter-over-quarter for the first time in more than one year as our new commercial strategy implemented after our strategic pivot in 2025 began to take hold,” said Shantanu Gaur, founder and CEO. “We have also continued to reduce our operating losses through a sharpening of our strategic focus, and, with that, I believe we have set ourselves up for an even more efficient 2026. With a potential FDA approval of our Allurion Smart Capsule on the horizon, I believe 2026 will be a historic year for Allurion.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion Technologies files to sell 5.99M shares of common stock for holders
- Allurion Shareholders Approve Governance Changes and Capital Actions
- Allurion reports initial results on Allurion Program, tirzepatide combination
- Allurion partners with ProSurg to pioneer new weight loss approach in Brazil
- Allurion Technologies Delays Q3 2025 Report Filing